• Clario accelerates your clinical trial from initiation to implementation. LEARN MORE →

Your using an unsupported browser. Please update to a modern browser for a better experience.
Skip to content
Clario
  • Solutions
    • eCOA Digital Solutions
      • eCOA Digital Solutions
      • eCOA Live
      • eCOA Multimedia
      • eCOA Rater and Participant Training
      • eCOA Rescue Studies
      • Suicidal Ideation
    • Cardiac Safety
      • Cardiac Safety
      • Arrhythmia Analysis
      • Blood Pressure Services
      • ECG — On-site to DCT and Phase I-IV
      • Phase I/TQT Cardiac Assessment
      • Regulatory Consultation and Statistical Analysis Expertise
    • Medical Imaging
      • Medical Imaging
      • Medical Imaging science team
      • FlexImaging
      • Image Redact AI
      • Image Repository
      • Imaging Platform
      • Image Workflow
      • Modalities
      • SMART Submit
    • Precision Motion
      • Precision Motion
      • Precision Motion: Scientific Consulting Services
      • Precision Motion: Scientific Publications
    • Respiratory Solutions
      • Respiratory Solutions
      • Cough and Lung Sounds
    • Trial Enablement
      • Trial Enablement
      • Clinical Adjudication
      • Clinical Trial Management
      • Electronic Data Capture (EDC)
      • Eligibility Solution
      • Payments
      • Randomization and trial supply management
      • Reporting & Analytics
      • Source Document Manager
    • Decentralized Trials
      • Decentralized Trials
      • eConsent
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
    • Oncology
    • Ophthalmology
    • Respiratory
  • Resources
    • Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Values & Culture
    • Security Governance
    • Corporate & Social Responsibility
    • Leadership
    • Scientific Expertise
    • Strategic Partnerships
    • Legal & Privacy
  • Support
  • Careers
    • Life at Clario
  • Newsroom
  • Login
  • Contact sales
    • Log in
    • Contact sales
  1. Home Resources Articles , , , Clario finds patients are as compliant at home as on-site

Clario finds patients are as compliant at home as on-site

Kelly Dumais, PhD – Senior Scientific Advisor 

Our research shows that oncology clinical trial patients are just as compliant when completing patient-reported outcomes (PROs) at home as they are when completing PROs on-site. These findings demonstrate that at-home PRO completion is a viable method for oncology clinical trials, which we believe will help accommodate the recommendations of increased PRO frequency by regulatory agencies.  

Both the Food and Drug Administration (FDA) and European Medicines Agency (EMA) recently emphasized the importance of more frequent PROs across more categories for investigational oncology compounds. They are calling for greater incorporation of the patient perspective and experience surrounding the risk/benefit evaluation of investigational oncology treatments. Most recently, the FDA released a 2021 Draft Guidance on Core PROs in Oncology Clinical Trials that emphasizes the collection of five PRO categories and more frequent collection of PROs, in some cases recommending weekly collection during the first few treatment cycles. 

With a full endpoint strategy, DCTs can meet the new regulatory requirements and effectively engage patients. DCT technologies can enable oncology patients who are not feeling well to meet increasing study requirements from the comfort of their homes, which could mean the difference between them participating or not having access to a life-changing therapy or not. 

Our Recommendations 

Following our research, we outlined recommendations for creating a PRO strategy that may better comply with the FDA and EMA recommendations, both on the types of PROs being collected and the frequency with which they are collected. Key recommendations include: 

  • For PRO strategies, Clario recommends including disease-specific assessments and/or patient-reported symptomatic adverse events.  
  • A shift away from on-site/tablet collection of PROs towards at-home handheld/BYOD PRO collection to accommodate more frequent (and more convenient) PRO collection without adding additional site visit burden is also recommended.  
  • When planning a PRO strategy for investigational products, the incorporation of wearables or precision motion to collect objective information on physical functioning should be a key consideration, as physical function is a key PRO category recommended by the FDA in its new guidance. 

To receive additional details and a copy of the poster, contact our science team at [email protected] 

Back to articles
Share
Twitter Facebook LinkedIn

Latest external publications

See all
Peer-Reviewed

Development, initial validation, and application of a visual read method for [18F]MK-6240 tau PET

Read
Trade Publication

Artificial Intelligence in Gastroenterology

Read
Peer-Reviewed

The E/e′ ratio: As “critical” as the left ventricular ejection fraction?

Read
Clario logo
    • Solutions
    • Therapeutic Areas
    • About
    • Resources
    • Careers
    • News
  • Get in touch

    • Contact
    • Support
    • Customer portal

Follow us

Twitter LinkedIn Glassdoor
×

Contact sales

If you are looking for a partner to help you generate the richest clinical evidence with the right clinical trial technology, please fill in the form below or send us an email.

Customer support

Questions regarding your clinical trial technology or need technical support? Our customer care teams are ready to help you.

Customer support

Media contact

If you would like to speak with one of our innovators or thought leaders, connect with our public relations team.

Email: [email protected]

Our Locations

View our locations

Thanks for your form. Our team will be in touch very soon.

  • © 2023 Clario

    • Legal and Privacy Terms
    • Security Governance
    • Cookie Policy
    • Impressum

Please enter your business email before proceeding to xTalks to complete registration.

×